Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)

Takashi Kojima1 · Ken Kato2 · Hiroki Hara3 · Shunji Takahashi4 · Kei Muro5 · Tomohiro Nishina6 · Masashi Wakabayashi7 · Shogo Nomura7 · Akihiro Sato7 · Atsushi Ohtsu1 · Toshihiko Doi1

Received: 11 December 2021 / Accepted: 30 May 2022 / Published online: 29 July 2022 © The Author(s) 2022

Abstract
Background PI3K/AKT/mTOR pathway is frequently overactive in esophageal squamous cell carcinoma (ESCC), making it an attractive treatment target. BKM120 is an oral pan-class I PI3K inhibitor with promising activity in several cancers. We prospectively investigated efficacy, safety, and biomarkers of BKM120 in advanced ESCC. We conducted a multicenter phase II study of BKM120 monotherapy in patients with pretreated advanced ESCC.

Methods BKM120 (100 mg/day) was administered orally in a 28-day cycle. The primary end point was disease control rate (DCR). Tumor samples for all patients were collected for gene alteration analysis in a comprehensive genomic profiling assay.

Results Of 42 patients enrolled, 20 had stable disease and two had confirmed partial response. One ineligible patient was excluded from the primary analysis, which met the primary end point (DCR 51.2%; 95% confidence interval [CI], 35.1–67.1). In the 42 patients, median progression-free survival and overall survival were 2.3 (95% CI 1.8–3.2) and 9.0 (95% CI 6.5–11.4) months, respectively. Common grade 3 or 4 adverse events were rash, anorexia, hyponatremia, and abnormal hepatic function; profiles of these events in this study were similar to those in previous studies of BKM120 monotherapy. No treatment-related deaths occurred. PI3K pathway activation was observed in patients with good clinical response.

Conclusions BKM120 monotherapy showed promising efficacy and a manageable toxicity profile even in patients with pretreated advanced ESCC. This study showed the potential target PI3K for ESCC, and further confirmatory trial will be necessary to confirm it. Unique ID issued by UMIN: UMIN 000011217.

Keywords NVP-BKM120 · Esophageal Neoplasms · Phosphatidylinositol 3-Kinases

Introduction
Esophageal cancer is the eighth most common cancer and the sixth most common cause of cancer-related death worldwide [1].

Patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) usually have a particularly poor prognosis, with a median overall survival (OS) from 6 to 10 months [2, 3], and there are few chemotherapeutic agents available. Commonly used agents include 5-fluorouracil, platinum agents, taxanes, and anti-PD-1 antibody. Although molecularly targeted agents substantially improve the outcome of several types of cancers, unfortunately no agent has shown clinically significant benefit in ESCC. While there is an unmet medical need in ESCC, clinical developments for new agents have not progressed because of ethnic differences in history, economic issues, and a lack of driver gene mutation.
EGFR overexpression occurs in 32–86% of ESCC. Although EGFR represents one of the most investigated molecular targets in ESCC, in recent clinical trials, combination treatment with anti-EGFR antibody and radiotherapy or conventional chemotherapy failed to show the additional treatment efficacy [4–6]. It had been reported that EGFR overexpression might be the relevant biomarker for activity of anti-EGFR antibody, and some report suggested that PI3KCA/PTEN gene deregulation significantly correlated with an impaired response to anti-EGFR antibody [7, 8].

The PI3K/AKT/mTOR pathway within cancer cells is important for tumor cell growth, proliferation, survival, motility, and metastasis. Recently, it was reported that the PI3K pathway also plays a role in leukocyte recruitment and activation, vascular integrity maintenance, and other aspects of the tumor microenvironment [9]. An activating PIK3CA mutation or amplification has been observed from 2.2 to 21% of patients with ESCC [10–13]. PIK3CA mutation may be possible a potential target molecule in ESCC.

BKM120 is a potent and highly specific oral class I phosphoinositide 3-kinase (PI3K) inhibitor that belongs to the 2,6-dimorpholino pyrimidine derivative family. BKM120 has demonstrated antiproliferative, proapoptotic, and antitumor activity in a variety of cell lines and xenograft models from cancers [14]. BKM120 demonstrated broad antitumor activity in a phase I clinical study [15–17]. As a potential predictive biomarker for PI3K inhibitors, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) mutations have been suggested in a review of early-phase clinical trials in various solid cancers [18].

In a phase I study involving an mTOR inhibitor (RAD001), one patient with ESCC demonstrated a partial response [19]; similarly, head and neck cancer patients demonstrated a partial response with BKM120 [15]. The results of a randomized phase II study in patients with platinum-treated head and neck cancer reported that BKM120 plus paclitaxel improves progression-free survival (PFS) compared with paclitaxel alone [20]. Therefore, we conducted this multicenter phase II study of BKM120 in patients with ESCC.

The aim of this phase II study was to assess the efficacy and safety of BKM120 monotherapy in patients with ESCC. We therefore performed exploratory biomarker analyses by next-generation sequencing-based comprehensive genomic profiling (FoundationOne) to predict the efficacy of BKM120 in this patient population.

**Patients and methods**

**Patient population**

Patients had to be aged ≥ 20 years and have the following characteristics: (1) histologically confirmed unresectable or recurrent ESCC refractory to one or two standard regimens that contained fluoropyrimidine and platinum derivatives; (2) discontinued the last prior chemotherapy before enrollment because of radiologic disease progression or an adverse event; (3) evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1); (4) Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2; (5) adequate bone marrow, hepatic, and renal function; and (6) fasting plasma glucose levels of ≤ 120 mg/dL. A tumor specimen (primary or metastatic) was acquired from archival material or fresh biopsy.

The key exclusion criteria were treatment with CYP3A4 modifier drug ≤ 1 week before starting BKM120, clinical manifestation of diabetes mellitus, clinically documented depression or anxiety on the Patient Health Questionnaire-9 and Generalized Anxiety Disorder Screener-7 mood scales, and previous treatment with PI3K/AKT/mTOR inhibitors.

**Study design**

This multicenter, phase II, open-label, single-arm study was conducted to evaluate the efficacy and safety of BKM120 monotherapy in ESCC at six Japanese institutions. The ethics committees (institutional review board) of the participating institutions and regulatory authorities approved this study. All patients provided informed consent. The study followed the Declaration of Helsinki and Good Clinical Practice guidelines. The study was registered at the UMIN clinical trials registry (http://www.umin.ac.jp/ctr/index-j.htm; registration number UMIN000011217).

**Study treatment and assessment**

All patients received BKM120 (100 mg/day) until disease progression, unacceptable toxicity, or withdrawal of consent. In the case of adverse events (AEs) or toxicity considered to be related to BKM120, dosing was delayed or reduced according to an algorithm outlined in the study protocol.

Each investigator evaluated antitumor response at 4 and 8 weeks after treatment initiation and then every
4–6 weeks in accordance with RECIST guidelines. When treatment was discontinued for any reason other than progressive disease, follow-up imaging was performed according to the planned schedule until disease progression or subsequent anticancer treatment.

The primary end point was the investigator-assessed disease control rate (DCR), which was defined as the proportion of patients with the best overall response of complete response (CR), partial response (PR), or stable disease (SD) based on the RECIST guidelines.

DCR was analyzed in the per-protocol set over 8 weeks (PPS8W), which included a subset of eligible patients who fulfilled the minimum exposure requirement (relative dose of ≥ 0.5) until 8 weeks or who experienced progression before the minimum exposure requirement without any major protocol deviation. Imaging data of patients with investigator-assessed CR, PR, or SD (best response) were independently reviewed by a single radiologist who had 5 years or more of subspecialty experience in diagnostic oncologic radiology.

The secondary efficacy end points were objective response rate (ORR), OS, and PFS, all analyzed in the per-protocol set, which included a subset of eligible patients. ORR was defined as the proportion of patients with the best overall response of CR or PR based on the RECIST guidelines. OS was defined as the time from enrollment until death from any cause. PFS was defined as the time from enrollment until tumor progression, as determined by investigator assessment, or death from any cause.

Safety analysis was performed in the safety population (SP), which comprised patients who received BKM120 monotherapy. AEs were assessed according to the Common Terminology Criteria for AEs (version 4.0).

### Statistical plan

The study used Simon’s minimax two-stage design with a one-sided α level of 10% and power of 90%. A DCR of 40% was considered nonpromising, whereas a DCR of 60% was considered promising in this population. In the first stage, 28 PPS8W patients were to be enrolled, and termination of the trial was considered if ≤ 11 patients achieved CR, PR, or SD. In the second stage, 13 additional PPS8W patients were to be enrolled. Of the total 41 PPS8W patients, the null hypothesis of DCR of 40% would be rejected if ≥ 21 patients achieved CR, PR, or SD.

The ORR and DCR, and their exact binomial 95% confidence intervals (CI), were estimated. The Kaplan–Meier method was used to analyze PFS and OS, with estimates for median time-to-event end points and their 95% CIs. All statistical analyses were performed using SAS software (release 9.4; SAS Institute, Inc., Cary, NC).

### Biomarker analysis

Exploratory biomarker analysis was performed on a subset of tumor samples, and sufficient material was available. (In cases where tumor samples could not be collected by biopsy, but archival tumor samples were available, the use of archival tumor samples was also permitted.) Next-generation sequencing-based comprehensive genomic profiling was performed on all formalin-fixed paraffin-embedded tissues using a hybrid capture-based next-generation sequencing platform (FoundationOne; Foundation Medicine, Cambridge, MA) at a Clinical Laboratory Improvement Amendments–certified, New York State and College of American Pathologists–accredited laboratory (Foundation Medicine) on the Illumina HiSeq2500 instruments (Illumina, Inc., San Diego, CA).

### Results

#### Patient characteristics

From August 2013 to August 2016, 42 patients (median age 62.5 years; ECOG performance status 0/1 = 28/14) were enrolled in this study. After enrollment, one patient treated with BKM120 was found to be ineligible because of three prior treatment regimens received, and the patient was excluded from PPS8W. In the first stage, DCR was 53.6% (15 of 28 PPS8W patients achieved SD). Therefore, we enrolled an additional 13 patients in the second stage. All 42 enrolled patients were assessable as the SP.

All patients had received fluoropyrimidine and platinum agents, whereas 31 patients (73.8%) had received taxanes. A total of 22 patients had previously undergone esophagectomy (52.4%; Table 1).

#### Exposure to chemotherapy

Patients underwent treatment for a median duration of 57 days (range 5–225 days); 17 patients (40.5%) required a dose reduction and 27 (64.3%) interrupted their treatment. The relative dose intensity of BKM120 was maintained in all treatment periods (median 95.7%; range 42.7–100%), and most patients (78.6%) were treated until disease progression (Table 2).

#### Antitumor activity

The best overall responses were evaluated by investigators and an independent radiologic review (Table 3). A total of 42 patients, including one ineligible patient excluded from the primary analysis, were evaluable for response by investigator review of target lesion radiologic assessments. Of the
42 patients, two achieved confirmed PR, the ORR was 4.8%, and DCR was achieved by 52.4% of all patients. The investigators’ assessments of the PPS8W population revealed that one patient achieved PR and 20 achieved SD, which corresponded to an investigator-assessed DCR of 51.2% (95% CI 35.1–67.1). A total of 21 patients achieved DCR, which exceeded the threshold of 20 patients. Although no patient achieved CR, the tumor size decreased in 54.8% of patients (Fig. 1).

During the independent central review for 33 patients, the radiologist concluded that two patients who were classified as having SD by the investigator assessment actually had PR. Therefore, the relative risk according to the independent central review was 9.5%.

At the data cutoff date (March 6, 2017), all patients except one had experienced disease progression, and one had PR. The median investigator-assessed PFS was 2.3 months (95% CI 1.8–3.2 months; Fig. 2A). After a median follow-up of 9.2 months, the median OS was 9.0 months (95% CI 6.5–11.4 months; Fig. 2B).

**Safety findings**

BKM120 monotherapy was well tolerated by all patients. The most common grade 3 or 4 AEs were maculopapular rash (9.5%), anorexia (7.1%), aspartate aminotransferase increase (4.8%), alanine aminotransferase increase (4.8%), diarrhea (4.8%), fatigue (4.8%), hyperglycemia (2.4%), and oral mucositis (2.4%), the profiles of which were similar to those of previous studies of BKM120 monotherapy (Table 4). No treatment-related deaths occurred.

**Biomarker analysis**

Thirty-five tumor samples were found to be evaluable; eight (23%) had PI3K pathway alterations (Fig. 1), including PIK3CA mutation (n = 2), PIK3CA amplification (n = 3), phosphatase and tensin homolog (PTEN) mutation (n = 2), and PTEN loss (n = 2). The missense mutation p.F354L in exon 8 of the serine/threonine kinase 11 (STK11) gene was identified in three cases.

Waterfall plots are shown in Fig. 1. The first patient with PR had PIK3CA amplification and experienced a 63% reduction in target lesion size. Time to response was 97 days and duration of response was 132 days. The second patient with PR had PIK3CA mutations and experienced a 40% reduction in target lesion size. Time to response was 29 days and duration of response was 114 days.

**Discussion**

This study was designed to evaluate the efficacy and safety of BKM120 monotherapy in patients with recurrent or metastatic ESCC. The primary end point of the study (i.e., a promising DCR) was met by 51.2% (95% CI 35.1–67.1) of pretreated patients with ESCC. In addition, 54.8% of patients demonstrated tumor shrinkage from baseline. The median PFS was 2.3 months, and the median OS was 9.0 months.

![Image](https://via.placeholder.com/150)

**Table 1** Patient Characteristics (n = 42)

| Characteristic | n (%) |
|---------------|-------|
| Sex, male     | 38 (81.0) |
| Age, median (years) | 62.5 |
| ECOG performance status | |
| 0             | 28 (66.7) |
| 1             | 14 (33.3) |
| Previous esophagostomy | |
| Yes           | 22 (52.4) |
| No            | 20 (47.6) |
| Previous radiotherapy | |
| Yes           | 24 (57.1) |
| No            | 18 (42.9) |
| No. of prior regimens | |
| 1             | 12 (28.6) |
| 2             | 29 (69.0) |
| 3             | 1 (2.4) |
| Prior treatment | |
| Fluoropyrimidine + platinum | 35 (83.3) |
| Taxanes       | 24 (57.1) |
| DCF<sup>a</sup> | 10 (23.8) |
| Immune checkpoint inhibitor | 3 (7.1) |

Abbreviation: ECOG Eastern Cooperative Oncology Group

<sup>a</sup>DCF: 5-fluorouracil + cisplatin + docetaxel

**Table 2** Exposures (n = 42)

| Relative Dose Intensity | |
|-------------------------|-----------------|
| At 8 weeks, median, % (range) | 96.4 (48.6–100.0) |
| All periods, median, % (range) | 95.7 (42.7–100.0) |
| No. of days, median (range) | 57 (5–225) |
| Dose reduction, n (%) | 17 (40.5) |
| Interruption, n (%) | 27 (64.3) |
| Reasons for discontinuation | |
| Disease progression, n (%) | 33 (78.6) |
| AEs, n (%) | 4* (9.5) |
| Patient refusal, n (%) | 3 (7.1) |
| Other, n (%) | 2 (4.8) |

Abbreviation: AEs adverse events

<sup>*</sup>Maculopapular rash (1), syncope (1), fatigue and GGT increased (1), hepatic disorder (1)
The choice of DCR as the primary end point in this study was considered appropriate because it reflects clinical practice, where progression usually necessitates a change of treatment; also, its use is appropriate in a proof-of-concept study in the second- and third-line settings. Patients in this study were previously treated; nearly 70% received BKM120 as a third-line therapy.

BKM120 was generally well tolerated, and no new safety concerns were identified in the study. The three main categories of AEs suspected to be related to BKM120 were hyperglycemia, liver function abnormalities, and mood disorders. The most common grade 3 or 4 AEs were anorexia, rash, hyponatremia, lipase increase, and abnormal hepatic function (including increased transaminase levels), the profiles of which were similar to those of previous studies of BKM120 monotherapy [15, 21].

Preliminary signs of clinical efficacy were observed in this study, with two patients (4.8%) exhibiting PR. The DCR reported here (52.4%) was similar to rates observed with BKM120 in other patient populations: 41% and 40% in Western and Japanese patient populations, respectively [15, 17].

Among patients with a known gene alteration status, PI3K activation (defined as PIK3CA mutation, PIK3CA

**Fig. 1** Waterfall plot (n = 42). Radiologic response to BKM120 with corresponding status of tumor PIK3CA, PTEN, and STK11. DCR disease control rate, PD progressive disease, PIK3CA phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, PR partial response, PTEN phosphatase and tensin homolog, RR relative risk, SD stable disease, STK11 serine/threonine kinase 11

| Table 3 Overall response | By the investigators | Central review |
|--------------------------|----------------------|----------------|
|                         | n=41 PPS8W | n=42 | n=41 PPS8W | n=42 |
| CR | n | % | n | % | n | % | n | % |
| PR | 1 | 2.4 | 0 | 0 | 0 | 0 | 0 | 0 |
| SD | 20 | 48.8 | 20 | 47.6 | 18 | 43.9 | 18 | 42.8 |
| PD | 20 | 48.8 | 20 | 47.6 | 20 | 48.8 | 20 | 47.6 |
| DCR (95% CI) | 51.2 (35.1–67.1) | 52.4 (36.4–68.0) |
| RR (95% CI) | 2.4 (0.1–12.9) | 4.8 (0.6–16.2) |

CI confidence interval, CR complete response, DCR disease control rate, PD progressive disease, PPS8W per-protocol set over 8 weeks, PR partial response, RR relative risk, SD stable disease
amplification, *PTEN* mutation, and *PTEN* loss) was exhibited in 19% (8/42) of patients with ESCC. The observed frequency of PI3K pathway alterations in ESCC was similar to that reported by a previous study of The Cancer Genome Atlas, in which approximately 21% of 90 patients exhibited *PIK3CA* mutations or *PTEN* alterations [22]. In our study, seven of eight patients with PI3K activation demonstrated tumor shrinkage from baseline, and two patients achieved PR.

Although it is possible that BKM120 will show greater efficacy in patients with activated PI3K signaling, this study contained too few patients to determine any correlation between mutation status and response. The correlation between PI3K activation status and clinical response is not conclusive based on results from previous trials of BKM120 and other PI3K inhibitors [16, 17, 23–26]. Further research is needed to determine if PI3K activation status is a predictor of BKM120 response and whether selecting for patients with PI3K activation could improve outcomes with BKM120.

In our study, all three patients with mutations in *STK11* demonstrated tumor shrinkage and had a missense mutation at amino acid 354, leading to conversion of the wild-type residue phenylalanine to a leucine (*STK11*, p.F354L, c.1062C > G). The serine/threonine kinase *STK11* (also called LKB1) activates AMP-activated protein kinase (AMPK) and negatively regulates the mTOR pathway in response to changes in cellular energy levels [27]. The F354L mutation has been shown to impair STK11-mediated AMPK activation and lead to increased mTOR signaling [29].

As with many early-phase studies with other PI3K inhibitors in advanced solid tumors, no association was identified between the extent of tumor shrinkage or best overall response, as per investigator assessment, and the tumor

**Fig. 2** A Progression-free survival. B Overall survival. *n* = 42. CI confidence interval, *OS* overall survival, *PFS* progression-free survival.
molecular alterations analyzed. This lack of association could be due to several factors, such as the small sample size, time lag between the archival sample used for pathway analysis and the time of patient entry in the trial, and heterogeneous patient population.

In conclusion, BKM120 monotherapy showed promising efficacy and a mild toxicity profile in patients with pretreated advanced ESCC. PI3K inhibitors, such as BKM120, are worthy of further evaluation in confirmatory studies.

Acknowledgements

We would like to thank the patients, their families, the nurses, and the investigators who participated in this study. This study was conducted by the EPOC Data Center, a non-profit organization. This study was funded by Novartis Pharma K.K. BKM120 was provided by Novartis Pharma K.K. The funder of the study had no role in study design, data collection, analysis, or interpretation, or writing of the report.

Declarations

Conflict of interest

Takahashi Kojima has received grants from MSD, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Astellas, Amgen Biopharma, Taiho Pharmaceutical, Chugai Pharmaceutical Co. Ltd., and Shionogi; and honoraria from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, MSD, Astellas Pharma, Merck, and Oncolyt Biopharma. Ken Kato has received grants from Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd., MSD, BeiGene, Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical, AstraZeneca, BAYER, Shionogi, and Novartis; consulting fees from BMS, ONO, and BeiGene; honoraria from Bristol Myers Squibb and ONO; and Participation on advisory board from Daiichi Sankyo. Hiroki Hara has received grants from Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Elevare Therapeutics, GSK, Incyte, Merck Biopharma, MSD K. K., Ono, Pfizer, and Taiho Pharmaceutical; consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Lilly, MSD K. K., and Ono; and honoraria from Bayer, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Hakko Kirin, Lilly, Merck Biopharma, MSD K. K., Ono, Sanofi, Taiho Pharmaceutical, Takeda, and Yakult Honsha. Shunji Takahashi has received grants from Eisai, Novartis, and Taiho Pharmaceutical; and honoraria from Eisai, Novartis, and Taiho Pharmaceutical. Kei Muro has received all support for the present manuscript from Novartis Pharma K.K.; grants from Astellas, Amgen, Sanofi K. K., Daiichi Sankyo, Parexel International, Taiho, MSD, Merck Biopharma Co., Ltd., Pfizer Inc., Eisai Co., Ltd., Solsia Pharma K.K., and Ono Pharmaceutical Co., Ltd.; consulting fees from Amgen, Ono Pharmaceutical Co., Ltd., and AstraZeneca; honoraria from Eli Lilly, Chugai Pharmaceutical Co. Ltd., Takeda, Ono Pharmaceutical Co., Ltd., Taiho, Sanofi, Bristol Myers Squibb, and Bayer. Tomohiro Nishina has received honoraria from Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo, and Bristol Myers Squibb. Shogo Nomura has received a grant for Amgen, and AstraZeneca; and Honoraria from

Table 4  Major adverse events (> 10% of any grade; n = 42)

| Adverse event                                      | Any grade, n (%) | Grade 3/4, n (%) |
|----------------------------------------------------|------------------|-----------------|
| Hyperglycemia                                      | 24 (57.1)        | 1 (2.4)         |
| Maculopapular rash                                 | 20 (47.6)        | 4 (9.5)         |
| Anorexia                                           | 13 (31.0)        | 3 (7.1)         |
| Aspartate aminotransferase increase                | 13 (31.0)        | 2 (4.8)         |
| Oral mucositis                                     | 13 (31.0)        | 1 (2.4)         |
| Alanine aminotransferase increase                  | 11 (26.2)        | 2 (4.8)         |
| Nausea                                             | 10 (23.8)        | 0               |
| Diarrhea                                           | 8 (19.0)         | 2 (4.8)         |
| C-peptide increase                                 | 8 (19.0)         | 0               |
| Malaise                                            | 8 (19.0)         | 0               |
| Anxiety                                            | 7 (16.7)         | 0               |
| Dry skin                                           | 7 (16.7)         | 0               |
| Fatigue                                            | 6 (14.3)         | 2 (4.8)         |
| Vomiting                                           | 6 (14.3)         | 0               |
| Depression                                         | 5 (11.9)         | 0               |
| Platelet count decrease                            | 5 (11.9)         | 0               |
| Dysgeusia                                          | 5 (11.9)         | 0               |
| Lipase increase                                    | 4 (9.5)          | 3 (7.1)         |
| Alkaline phosphatase increase                      | 3 (7.1)          | 0               |
| Creatinine increase                                | 3 (7.1)          | 0               |
| Fever                                              | 3 (7.1)          | 0               |
| Hypertension                                       | 3 (7.1)          | 0               |
| Hyponatremia                                       | 3 (7.1)          | 3 (7.1)         |
| Photosensitivity                                   | 3 (7.1)          | 1 (2.4)         |
| Palmar-plantar erythrodysesthesia syndrome         | 3 (7.1)          | 0               |

No treatment-related deaths were observed.
AstraZeneca, Pfizer, Taiho, and Chugai. Akihiko Sato has received a grant from Novartis Pharma. Toshiko Doi has received grants from Lilly, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Merck Serono, Janssen Pharma, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, AbbVie, IQVIA, and Eisai; consulting fees from Sumitomo Dainippon, Taiho, Takeda, Chugai Pharmaceutical Co. Ltd. Pharma, AbbVie, Bayer, Rakuten Medical, and Otsuka Pharma; honoraria from Bristol-Myers Squibb, Rakuten Medical, Ono Pharma, Oncolys BioPharma, and Taiho; and advises on the boards of MSD, Daiichi Sankyo, Amgen, Novartis, Boehringer Ingelheim, Janssen Pharma, AbbVie, Bayer, and Astellas Pharma. Masashi Wakabayashi and Atsushi Ohitsu report no conflict of interest.

**Ethical statement** This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent. The study protocol was approved by the institutional review board at each study site.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

2. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172–6.

3. Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCG9407). Jpn J Clin Oncol. 2001;31:419–23.

4. Lorenzen S, Schuster T, Porsch R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomised phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20:1667–73.

5. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14:627–37.

6. Suntharalingam M, Winter K, Ilson D, et al. Effect of the addition of Cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 Randomized Clinical Trial. JAMA Oncol. 2017;3:1520–8.

7. Perrone F, Lampis A, Orsenigo M, et al. PIK3CA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009;20:84–90.

8. de la Rochefordiere A, Kamal M, Fioquet A, et al. PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy +/- cetuximab in cervical cancer patients. Clin Cancer Res. 2015;21:2530–7.

9. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497–510.

10. Wang L, Shan L, Zhang S, et al. PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma. PLoS One. 2014;9: e103021.

11. Hatogai K, Fujii S, Kojima T, et al. Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma. BMC Cancer. 2017;17:36.

12. Shigaki H, Baba Y, Watanabe M, et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res. 2013;19:2451–9.

13. Mori R, Ishiguro H, Kimura M, et al. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res. 2008;145:320–6.

14. Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11:317–28.

15. Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014;105:347–53.

16. Bendell JC, Roden J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30:282–90.

17. Roden J, Braña I, Siu LL, et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014;32:670–81.

18. Janku F, Hong DS, Fu S, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014;6:377–87.

19. Okamoto I, Doi T, Ohtsu A, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 2010;40:17–23.

20. Soulieres D, Faire V, Mesia R, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18:323–35.

21. Heudel PE, Fabbro M, Roemer-Becuwe C, et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. Br J Cancer. 2017;116:303–9.

22. The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2015;524:169–75.

23. Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev. 2013;39:313–20.

24. Janku F, Tsimeridou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2013;10:558–65.

25. Janku F, Weler J, Westin SN, et al. PIK3CA/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30:777–82.

26. Vansteenkiste JF, Canon JL, De Braud F, et al. Safety and efficacy of PI3K pathway-activated non-small cell lung cancer: results from the Phase II BASALT-1 Study. J Thoracic Oncol. 2015;10:1319–27.
27. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91–9.

28. Carretero J, Shimamura T, Rikova K, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 2010;17:547–59.

29. Forcet C, Etienne-Manneville S, Gaude H, et al. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum Mol Genet. 2005;14:1283–92.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.